Occlutech International AB - Product Pipeline Analysis, 2024 Update
Summary
Occlutech International AB (Occlutech) is a medical device company that develops and supplies heart implant products. The company's products include occluders, occlutech atrial flow regulator (AFR), accessory medical devices (AFR), among others. Atrial flow regulator (AFR) is a cardiac implant designed to address the needs of patients suffering from heart failure. It operates through research and development, and production facilities located in Germany, the UK, Italy, France, Benelux, the Nordics, Australia, New Zealand and Canada, among others. Occlutech is headquartered in Helsingborg, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Occlutech International AB
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Occlutech International AB Company Overview
Occlutech International AB Company Snapshot
Occlutech International AB Pipeline Products and Ongoing Clinical Trials Overview
Occlutech International AB – Pipeline Analysis Overview
Occlutech International AB - Key Facts
Occlutech International AB - Major Products and Services
Occlutech International AB Pipeline Products by Development Stage
Occlutech International AB Ongoing Clinical Trials by Trial Status
Occlutech International AB Pipeline Products Overview
Occlutech Figulla Flex II ASD Occluder Product Overview
Occlutech Figulla Flex II ASD Occluder Clinical Trial
Occlutech Figulla Flex II PFO Occluder
Occlutech Figulla Flex II PFO Occluder Product Overview
Occlutech Figulla Flex II PFO Occluder Clinical Trial
Occlutech Figulla Flex UNI
Occlutech Figulla Flex UNI Product Overview
Occlutech International AB - Key Competitors
Occlutech International AB - Key Employees
Occlutech International AB - Locations And Subsidiaries
Head Office
Recent Developments
Occlutech International AB, Recent Developments
Aug 28, 2024: Occlutech Announces Commercial Cases of Occlutech ASD Occluder Device Implantation in the U.S.
Jan 08, 2024: Occlutech Announces FDA Approval of its Occlutech ASD Occluder and Occlutech Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects
Occlutech Atrial Flow Regulator (AFR) Device - A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech Atrial Flow Regulator in Heart Failure Patients
Occlutech Atrial Flow Regulator (AFR) Device - Flow Regulation by Opening the SepTum in Patients with Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
Occlutech Atrial Flow Regulator (AFR) Device - Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients with Pulmonary Hypertension
Occlutech Figulla Flex II ASD Occluder - Product Status
Occlutech Figulla Flex II ASD Occluder - Product Description
Occlutech Figulla Flex II ASD Occluder - Comparative Effectiveness of Three Devices for Transcatheter Closure of Atrial Septal Defects for Adults: A Pilot Study (Trio-ASD)
Occlutech Figulla Flex II ASD Occluder - Study to Evaluate the Efficacy of Occlutech ASD Occluder in the Treatment of Atrial Septal Defects
Occlutech Figulla Flex II PFO Occluder - Product Status
Occlutech Figulla Flex II PFO Occluder - Product Description
Occlutech Figulla Flex II PFO Occluder - Prospective Randomized Multi-center Controlled Clinical Investigation Comparing Patent Foramen Ovale (PFO) Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
Occlutech Figulla Flex UNI - Product Status
Occlutech Figulla Flex UNI - Product Description
Occlutech International AB, Key Employees
Glossary
List of Figures
Occlutech International AB Pipeline Products by Equipment Type
Occlutech International AB Pipeline Products by Development Stage
Occlutech International AB Ongoing Clinical Trials by Trial Status